Galapagos NV
GLPG
#4539
Rank
โ‚ฌ1.84 B
Marketcap
27,60ย โ‚ฌ
Share price
2.21%
Change (1 day)
6.85%
Change (1 year)

Revenue for Galapagos NV (GLPG)

Revenue in 2025 (TTM): โ‚ฌ0.28 Billion

According to Galapagos NV's latest financial reports the company's current revenue (TTM ) is โ‚ฌ0.27 Billion. In 2024 the company made a revenue of โ‚ฌ0.27 Billion an increase over the revenue in the year 2023 that were of โ‚ฌ0.11 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Galapagos NV from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚ฌ0.28 B4.09%
2024 โ‚ฌ0.27 B130.8%
2023 โ‚ฌ0.11 B-76.36%
2022 โ‚ฌ0.50 B4.21%
2021 โ‚ฌ0.48 B3.96%
2020 โ‚ฌ0.46 B-44.81%
2019 โ‚ฌ0.84 B192.55%
2018 โ‚ฌ0.28 B127.28%
2017 โ‚ฌ0.12 B-1.88%
2016 โ‚ฌ0.12 B227.37%
2015 โ‚ฌ39.56 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
AstraZeneca
AZN
โ‚ฌ49.62 B 18,056.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Johnson & Johnson
JNJ
โ‚ฌ78.67 B 28,683.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚ฌ40.57 B 14,744.74%๐Ÿ‡ซ๐Ÿ‡ท France
AbbVie
ABBV
โ‚ฌ50.92 B 18,530.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Fortress Biotech
FBIO
โ‚ฌ50.63 M-81.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
โ‚ฌ37.43 B 13,594.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚ฌ14.32 B 5,140.08%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
GlaxoSmithKline
GSK
โ‚ฌ36.16 B 13,129.14%๐Ÿ‡ฌ๐Ÿ‡ง UK
Merck
MRK
โ‚ฌ54.84 B 19,964.19%๐Ÿ‡บ๐Ÿ‡ธ USA